The following is a summary of the Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Inventiva reported Q4 revenues of €17.5 million, a rise of 40% compared to the previous year, primarily driven by milestones achieved with its Chinese partner.

• R&D expenditure surged by 82%, reflecting the accelerated clinical development for NATiV3.

• The company experienced a net loss of €110.4 million for the year, higher than the €54.3 million loss in 2022.

• Inventiva secured approx. $39 million through equity issues, $50 million from Chinese partner and an additional $10 million from a licensing agreement with Pharma.

• The global cash position stood at €61 million at the start of the year, a decline from €88.4 million the previous year.

Business Progress:

• Inventiva successfully implemented innovations in the Phase 3 Trials design for Lanifibranor, intended for MASH/NASH patients.

• Licensing of Lanifibranor in Japan and South Korea finalized via agreement with Palace Pharma.

• Positive interim results from a Phase 2 clinical trial were announced, showing both Lanifibranor alone and in combination with NMPA induced fat redistribution from visceral to subcutaneous areas, subsequently improving insulin sensitivity.

• Following approval by Chinese and EU authorities, Phase 3 trials began in China.

• The company expects to conclude enrollment for Phase 3 NATiV3 clinical trial by the first half of the year.

• The potential for Lanifibranor to be prescribed for 30% of MASH patients was highlighted in a recent physician survey.

• The company plans to have a slight increase in R&D expense in 2024, with a decrease expected by 2025, and is considering options to secure additional funding, including potential partnerships and accessing the capital market.

More details: Inventiva IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.